Humanwell Healthcare (Group) Co Ltd (600079) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
42
About the Report
About the Report
Summary
Humanwell Healthcare (Group) Co Ltd (Humanwell), formerly Wuhan Humanwell Hi-Tech Industry Co Ltd is a pharmaceutical company that offers generic products. The company offers pharmaceutical, medical instrument and reproductive health care products and technologies. Its products include anesthetics, biological products, herbal medicines, CNS medicines, women's health, anti-infection drugs, medical devices, OTC medicines and other products. Humanwell also provides buflomedil hydrochloride injectable, pantoprazole sodium injectable, omeprazole sodium injectable, phloroglucinol injectable, and simvastatin capsules. The company produces products in the forms of injection, tablets, syrup, granules, capsules, and suspension. It has partnership with other research institutes for investments, commercial distribution and research and development. Humanwell is headquartered in Wuhan, China.
Humanwell Healthcare (Group) Co Ltd (600079)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Humanwell Healthcare (Group) Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Humanwell Healthcare (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Ambrx Raises USD45 Million in Venture Financing 13
Private Equity 15
AGIC Capital Acquires Ritedose From Olympus Partners 15
Licensing Agreements 17
Elite Pharma Enters into Licensing Agreement with Epic Pharma for Abuse-Deterrent ELI-200 17
Elite Pharma Enters Into Licensing Agreement With Epic Pharma For Twelve Generic Products 18
Equity Offering 19
Humanwell Healthcare Decreases Size of Private Placement of Shares for USD174 Million 19
Wuhan Humanwell Healthcare Plans Private Placement of Shares for up to USD412.5 Million 20
Wuhan Humanwell Hi-tech Industry Plans For Private Placement Of Shares For Up To USD 163 Million 21
Debt Offering 22
Humanwell Healthcare to Raise USD302 Million in Private Placement of Notes 22
Humanwell Healthcare Raises USD150.8 Million in First Tranche of 4.99% Public Offering of Notes Due 2018 23
Humanwell Healthcare to Raise USD296.81 Million in Commercial Paper Offering 24
Humanwell Healthcare Raises USD224 Million in Public Offering of Notes 25
Humanwell Healthcare Plans to Raise USD309 Million in Public Offering of Notes 26
Humanwell Healthcare to Raise up to USD155 Million in Public Offering of Bonds 27
Wuhan Humanwell Announces Public Offering Of Notes Due 2015 For USD 95 MIllion 28
Acquisition 29
CSL to Acquire Remaining 20% Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD102 Million 29
Humanwell Healthcare Sells Bio-Pharma Unit for USD53 Million 30
CSL Acquires 80% Equity Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD352 Million 31
Humanwell Healthcare and PuraCap Pharma Acquire 100% Stake in Epic Pharma 32
Humanwell Healthcare Acquires Epic RE Holdco for USD21 Million 34
Humanwell Healthcare Plans to Acquire 70% Stake in Chengdu Kanghong Pharma for USD53 Million 35
Humanwell Healthcare Plans to Sell Shenzhen Biotech Firm for USD36 Million 36
Humanwell Healthcare to Acquire Yichang Sanxia Pharmaceutical for USD71.06 Million 37
Humanwell Healthcare Plans to Acquire 70% Stake in Pharmaceutical Firm for USD40 Million 38
Humanwell Healthcare (Group) Co Ltd-Key Competitors 39
Humanwell Healthcare (Group) Co Ltd-Key Employees 40
Humanwell Healthcare (Group) Co Ltd-Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List of Figure
List of Figures
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Humanwell Healthcare (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humanwell Healthcare (Group) Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Humanwell Healthcare (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ambrx Raises USD45 Million in Venture Financing 13
AGIC Capital Acquires Ritedose From Olympus Partners 15
Elite Pharma Enters into Licensing Agreement with Epic Pharma for Abuse-Deterrent ELI-200 17
Elite Pharma Enters Into Licensing Agreement With Epic Pharma For Twelve Generic Products 18
Humanwell Healthcare Decreases Size of Private Placement of Shares for USD174 Million 19
Wuhan Humanwell Healthcare Plans Private Placement of Shares for up to USD412.5 Million 20
Wuhan Humanwell Hi-tech Industry Plans For Private Placement Of Shares For Up To USD 163 Million 21
Humanwell Healthcare to Raise USD302 Million in Private Placement of Notes 22
Humanwell Healthcare Raises USD150.8 Million in First Tranche of 4.99% Public Offering of Notes Due 2018 23
Humanwell Healthcare to Raise USD296.81 Million in Commercial Paper Offering 24
Humanwell Healthcare Raises USD224 Million in Public Offering of Notes 25
Humanwell Healthcare Plans to Raise USD309 Million in Public Offering of Notes 26
Humanwell Healthcare to Raise up to USD155 Million in Public Offering of Bonds 27
Wuhan Humanwell Announces Public Offering Of Notes Due 2015 For USD 95 MIllion 28
CSL to Acquire Remaining 20% Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD102 Million 29
Humanwell Healthcare Sells Bio-Pharma Unit for USD53 Million 30
CSL Acquires 80% Equity Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD352 Million 31
Humanwell Healthcare and PuraCap Pharma Acquire 100% Stake in Epic Pharma 32
Humanwell Healthcare Acquires Epic RE Holdco for USD21 Million 34
Humanwell Healthcare Plans to Acquire 70% Stake in Chengdu Kanghong Pharma for USD53 Million 35
Humanwell Healthcare Plans to Sell Shenzhen Biotech Firm for USD36 Million 36
Humanwell Healthcare to Acquire Yichang Sanxia Pharmaceutical for USD71.06 Million 37
Humanwell Healthcare Plans to Acquire 70% Stake in Pharmaceutical Firm for USD40 Million 38
Humanwell Healthcare (Group) Co Ltd, Key Competitors 39
Humanwell Healthcare (Group) Co Ltd, Key Employees 40
Humanwell Healthcare (Group) Co Ltd, Subsidiaries 41
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.